Home Industries Manufacturing Irish firm ClonBio Group plans to boost investment in Jefferson County biorefinery...

Irish firm ClonBio Group plans to boost investment in Jefferson County biorefinery to $500 million

The Aztalan Bio facility in Johnson Creek. Image courtesy of Aztalan Bio.

Dublin, Ireland-based ClonBio Group, a family-owned agribusiness that manufactures sustainable bioproducts from grains, will increase its investment to $500 million in a previously shuttered biorefinery in Jefferson County that the company acquired in 2022 The facility, located at W5289 Joe Turley Way between Jefferson and Johnson Creek, is operated by Aztalan Bio, a subsidiary of

Already a subscriber? Log in

To continue reading this article ...

Subscribe to BizTimes today and get immediate access to our Insider-only content and much more.

Learn More and Subscribe Now
Ashley covers startups, technology and manufacturing for BizTimes. She was previously the managing editor of the News Graphic and Washington County Daily News. In past reporting roles, covering education at The Waukesha Freeman, she received several WNA awards. She is a UWM graduate. In her free time, Ashley enjoys watching independent films, tackling a new recipe in the kitchen and reading a good book.
Dublin, Ireland-based ClonBio Group, a family-owned agribusiness that manufactures sustainable bioproducts from grains, will increase its investment to $500 million in a previously shuttered biorefinery in Jefferson County that the company acquired in 2022 The facility, located at W5289 Joe Turley Way between Jefferson and Johnson Creek, is operated by Aztalan Bio, a subsidiary of ClonBio Group. San Antonio, Texas-based Valero Energy Corp. previously operated the plant until shutting it down in 2021. ClonBio Group bought the mothballed ethanol plant several months before the passage of the federal Inflation Reduction Act in 2022. Over the last 18 months, ClonBio Group has invested $100 million to acquire and upgrade the plant, which is now the largest grain processing facility in Wisconsin. Following the passage of the IRA, ClonBio Group is planning to "rapidly increase" its investment in the facility by $400 million. The company is planning to complete this investment "over the coming years" instead of over the next decade, according to the announcement. The planned $500 million cumulative investment will support more than 1,000 local jobs, according to a Monday announcement from ClonBio Group. “This investment will lead to more than 1,000 direct and indirect jobs in Wisconsin. It will apply state-of-the-art science to underpin farming practices and farm incomes, whilst tackling emissions and climate change head on. It will drive the most efficient use of grain in the history of the United States," said Jeff Oestmann, chief executive officer of Aztalan Bio. "Every part of the corn kernel is going to be used efficiently to make starch based, fiber based, protein based and fat-based foods, feeds, and fuels, thereby promoting the circular economy and maximizing food security. ClonBio’s biorefinery will make U.S. farmers indispensable partners in both energy and food security globally." ClonBio Group is submitting an application the U.S. Department of Energy for a $400 million loan guarantee. The company proposes the use of IRA tax credits to support the construction of a combined heat and power plant and one of the largest cellulosic renewable natural gas plants in the United States. ClonBio biorefineries use natural processes to refine locally produced grain for use in a wide range of applications including proteins and fibers for human and animal nutrition, ethanol for a range of fuel and industrial uses and organic fertilizer for farming. The company earns revenues of about a $437 million a year, according to The Irish Times. Representatives with ClonBio Group did not immediately respond to questions Monday morning.

Stay up-to-date with our free email newsletter

Keep up with the issues, companies and people that matter most to business in the Milwaukee metro area.

By subscribing you agree to our privacy policy.

No, thank you.
Exit mobile version